Treatment > Tamoxifen

Abstract

A comparison of the relative chemosensitivity of human gliomas to tamoxifen and 
n-desmethyltamoxifen in vitro

Vertosick FT Jr, Selker RG, Randall MS, Kristofik MP, Rehn T

Center for Neuro-Oncology, West Penn Hospital, Pittsburgh

Tamoxifen has been shown to inhibit the proliferation of human gliomas in vitro.
This inhibition is independent of tamoxifen's known anti-estrogenic properties.
Tamoxifen is an inhibitor of protein kinase C (PKC), a calcium- and phospholipid-dependent serine kinase which plays a critical role in the proliferation of certain cell lines.
Gliomas overexpress PCK, and their growth rate is coupled to the level of this key enzyme.
As such, the effect of tamoxifen may be mediated by its inhibitory effect on PKC.
To further investigate this possibility, we compared the chemosensitivity of cultured glioma lines to both tamoxifen and N-desmethyltamoxifen (DMT).
DMT is the major metabolite of tamoxifen in humans and is a ten-fold more potent inhibitor of PKC.
Seven lines were tested using the standard MTT assay, which quantitates metabolically active cells colorimetrically using a tetrazolium dye.
Four of the seven lines were also tested using a tritiated thymidine uptake assay.
In the MTT assay, all seven lines showed significantly greater sensitivity to DMT, while three of the four lines tested in the thymidine uptake assay were more sensitive to DMT.
Correlation between the two assays was good.
The dose of tamoxifen required to produce a 50% inhibition of optical absorbance or thymidine uptake (ID50) was typically five- to ten-fold greater than the ID50 for DMT, approximating the relative strength of the two compounds as PKC inhibitors.
In addition to providing some support for the ypothesis that triphenylethylenes inhibit gliomas via PKC inhibition, these findings have clinical significance.
(ABSTRACT TRUNCATED AT 250 WORDS)

PMID: 7964994 [PubMed - indexed for MEDLINE]